Episode Details

Back to Episodes

CytoDyn's Leronlimab: A New Hope for Triple-Negative Breast Cancer

Published 5 days, 6 hours ago
Description

CytoDyns Triumph: From Scandal to Hope for Triple-Negative Breast Cancer - After a major scandal, Vancouver biotech firm CytoDyn has turned things around with their drug leronlimab, showing promising results in treating triple-negative breast cancer, one of the deadliest types.

Support the show:
Get a discount at https://solipillow.com/discount/dnn.

Advertise on DNN:
advertise@thednn.ai

This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.

View sources & latest updates:
https://sources.thednn.ai/13c3e68b63ee7314

Listen Now

Love PodBriefly?

If you like Podbriefly.com, please consider donating to support the ongoing development.

Support Us